Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Периоперационное ведение пациентов с нервно-мышечными заболеваниями

Список литературы

  1. Неврология: национальное руководство / под ред. Гусева Е.И., Коновалова А.Н., Скворцовой В.И., Гехт А.Б. – М.: ГЭОТАР-Медиа, 2009. – 1040 с.
  2. Неврология: национальное руководство. Краткое издание /под ред. Е. И. Гусева, А. Н. Коновалова, А. Б. Гехт. – М.: ГЭОТАР-Медиа, 2014. – 688 с.
  3. Senger D, Erbguth F. Critical-illness-Myopathie und -Polyneuropathie [Critical illness myopathy and polyneuropathy]. Med Klin Intensivmed Notfmed. 2017;112(7):589-596. doi:10.1007/s00063-017-0339-0
  4. Martin LJ, Price AC, Kaiser A, Shaikh AY, Liu Z. Mechanisms for neuronal degeneration in amyotrophic lateral sclerosis and in models of motor neuron death (Review). Int J Mol Med. 2000;5(1):3-13. doi:10.3892/ijmm.5.1.3
  5. Murphy OC, Messacar K, Benson L, et al. Acute flaccid myelitis: cause, diagnosis, and management. Lancet. 2021;397(10271):334-346. doi:10.1016/S0140-6736(20)32723-9
  6. Kapur S, Kumar S, Eagland K. Anesthetic management of a parturient with neurofibromatosis 1 and Charcot-Marie-Tooth disease. J Clin Anesth. 2007;19(5):405-406. doi:10.1016/j.jclinane.2007.03.001
  7. Dermietzel R. Gap junction wiring: a 'new' principle in cell-to-cell communication in the nervous system?. Brain Res Brain Res Rev. 1998;26(2-3):176-183. doi:10.1016/s0165- 0173(97)00031-3
  8. Hahn AF, Ainsworth PJ, Naus CC, Mao J, Bolton CF. Clinical and pathological observations in men lacking the gap junction protein connexin 32. Muscle Nerve Suppl. 2000;9:S39-S48.
  9. Agergaard J, Leth S, Pedersen TH, et al. Myopathic changes in patients with long-term fatigue after COVID-19. Clin Neurophysiol. 2021;132(8):1974-1981. doi:10.1016/j.clinph.2021.04.009
  10. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220-232. doi:10.1016/S0140-6736(20)32656-8
  11. Doykov I, Hällqvist J, Gilmour KC, Grandjean L, Mills K, Heywood WE. 'The long tail of Covid-19' - The detection of a prolonged inflammatory response after a SARS-CoV-2 infection in asymptomatic and mildly affected patients. F1000Res. 2020;9:1349. Published 2020 Nov 19. doi:10.12688/f1000research.27287.2
  12. Stålberg E, van Dijk H, Falck B, et al. Standards for quantification of EMG and neurography. Clin Neurophysiol. 2019;130(9):1688-1729. doi:10.1016/j.clinph.2019.05.008
  13. Vanhorebeek I, Latronico N, Van den Berghe G. ICU-acquired weakness. Intensive Care Med. 2020;46(4):637-653. doi:10.1007/s00134-020-05944-4
  14. Puthucheary Z, Harridge S, Hart N. Skeletal muscle dysfunction in critical care: wasting, weakness, and rehabilitation strategies. Crit Care Med. 2010;38(10 Suppl):S676-S682. doi:10.1097/CCM.0b013e3181f2458d
  15. Batt J, dos Santos CC, Cameron JI, Herridge MS. Intensive care unit-acquired weakness: clinical phenotypes and molecular mechanisms. Am J Respir Crit Care Med. 2013;187(3):238-246. doi:10.1164/rccm.201205-0954SO
  16. Stevens RD, Marshall SA, Cornblath DR, et al. A framework for diagnosing and classifying intensive care unit-acquired weakness. Crit Care Med. 2009;37(10 Suppl):S299-S308. doi:10.1097/CCM.0b013e3181b6ef67
  17. Griffiths RD, Hall JB. Intensive care unit-acquired weakness. Crit Care Med. 2010;38(3):779-787. doi:10.1097/CCM.0b013e3181cc4b53
  18. Schaefer AM, Taylor RW, Turnbull DM. The mitochondrial genome and mitochondrial muscle disorders. Curr Opin Pharmacol. 2001;1(3):288-293. doi:10.1016/s1471- 4892(01)00051-0
  19. Davison JE, Rahman S. Recognition, investigation and management of mitochondrial disease. Arch Dis Child. 2017;102(11):1082-1090. doi:10.1136/archdischild-2016-311370
  20. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7(3):365-368. doi:10.1038/85520
  21. Lindstrom JM. Acetylcholine receptors and myasthenia. Muscle Nerve. 2000;23(4):453-477. doi:10.1002/(sici)1097-4598(200004)23:4<453::aid-mus3>3.0.co;2-o
  22. Galassi G, Marchioni A. Comment on case series of COVID-19 in patients with myasthenia gravis: a single institution experience by Županić et al. Acta Neurol Belg. 2022;122(2):559-560. doi:10.1007/s13760-021-01746-7
  23. Anand P, Slama MCC, Kaku M, et al. COVID-19 in patients with myasthenia gravis. Muscle Nerve. 2020;62(2):254-258. doi:10.1002/mus.26918
  24. Muir R, Osbourn M, Dubois AV, et al. Innate Lymphoid Cells Are the Predominant Source of IL-17A during the Early Pathogenesis of Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2016;193(4):407-416. doi:10.1164/rccm.201410-1782OC
  25. Muppidi S, Guptill JT, Jacob S, et al. COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). Lancet Neurol. 2020;19(12):970-971. doi:10.1016/S1474- 4422(20)30413-0
  26. Lambert EH, Eaton LM, Rooke ED: Defect of neuromuscular conduction associated with malignant neoplasm. Am J Physiol 187:612-613, 1956
  27. Koch MC, Steinmeyer K, Lorenz C, et al. The skeletal muscle chloride channel in dominant and recessive human myotonia. Science. 1992;257(5071):797-800. doi:10.1126/science.1379744
  28. Fontaine B, Khurana TS, Hoffman EP, et al. Hyperkalemic periodic paralysis and the adult muscle sodium channel alpha-subunit gene. Science. 1990;250(4983):1000-1002. doi:10.1126/science.2173143
  29. Lehmann-Horn F, Jurkat-Rott K. Voltage-gated ion channels and hereditary disease. Physiol Rev. 1999;79(4):1317-1372. doi:10.1152/physrev.1999.79.4.1317
  30. Newsom-Davis J, Mills KR. Immunological associations of acquired neuromyotonia (Isaacs' syndrome). Report of five cases and literature review. Brain. 1993;116 (Pt 2):453-469. doi:10.1093/brain/116.2.453
  31. Arimura K, Sonoda Y, Watanabe O, et al. Isaacs' syndrome as a potassium channelopathy of the nerve. Muscle Nerve Suppl. 2002;11:S55-S58. doi:10.1002/mus.10148
  32. Dalakas MC. Guillain-Barré syndrome: The first documented COVID-19-triggered autoimmune neurologic disease: More to come with myositis in the offing. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e781. Published 2020 Jun 9. doi:10.1212/NXI.0000000000000781
  33. Li Z, Li X, Shen J, Chan MTV, Wu WKK. Miller Fisher syndrome associated with COVID- 19: an up-to-date systematic review. Environ Sci Pollut Res Int. 2021;28(17):20939-20944. doi:10.1007/s11356-021-13233-w
  34. Suh J, Amato AA. Neuromuscular complications of coronavirus disease-19. Curr Opin Neurol. 2021;34(5):669-674. doi:10.1097/WCO.0000000000000970
  35. Paliwal VK, Garg RK, Gupta A, Tejan N. Neuromuscular presentations in patients with COVID-19. Neurol Sci. 2020;41(11):3039-3056. doi:10.1007/s10072-020-04708-8
  36. Lehmann HC, Schoser B, Wunderlich G, Berlit P, Fink GR. Neuromuskuläre Komplikationen einer SARS-CoV-2-Infektion – Teil 1: periphere Nerven [Neuromuscular complications of SARS-CoV-2 infections-Part 1: peripheral nerves]. Nervenarzt. 2021;92(6):540-547. doi:10.1007/s00115-021-01094-0
  37. Lehmann HC, Schoser B, Wunderlich G, Berlit P, Fink GR. Neuromuskuläre Komplikationen einer SARS-CoV-2-Infektion – Teil 2: Erkrankungen der Muskulatur [Neuromuscular complications of SARS-CoV-2 infection-Part 2: muscle disorders]. Nervenarzt. 2021;92(6):548-555. doi:10.1007/s00115-021-01093-1
  38. Islam B, Ahmed M, Islam Z, Begum SM. Severe acute myopathy following SARS-CoV-2 infection: a case report and review of recent literature. Skelet Muscle. 2021;11(1):10. Published 2021 Apr 21. doi:10.1186/s13395-021-00266-5
  39. Palaiodimou L, Stefanou MI, Katsanos AH, et al. Prevalence, clinical characteristics and outcomes of Guillain-Barré syndrome spectrum associated with COVID-19: A systematic review and meta-analysis. Eur J Neurol. 2021;28(10):3517-3529. doi:10.1111/ene.14860
  40. Talbott EO, Malek AM, Lacomis D. The epidemiology of amyotrophic lateral sclerosis. Handb Clin Neurol. 2016;138:225-238. doi:10.1016/B978-0-12-802973-2.00013-6
  41. Naguib M, Lien CA. Pharmacology of muscle relaxants and their antagonists // In Miller RD (ed): Miller's Anesthesia, 6th ed. New York, Churchill Livingstone, 2005, pp 481-572.
  42. Laghi F, Tobin MJ. Disorders of the respiratory muscles. Am J Respir Crit Care Med. 2003;168(1):10-48. doi:10.1164/rccm.2206020
  43. Juel VC, Bleck TP. Neuromuscular disorders in the ICU // Fink M.P., Abraham E., Vincent J.-L., Kochanek P.M. Textbook of Critical Care (5 eds.), 2005.
  44. EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis:, Andersen PM, Abrahams S, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)-revised report of an EFNS task force. Eur J Neurol. 2012;19(3):360-375. doi:10.1111/j.1468-1331.2011.03501.x
  45. Nicholson G, Myers S. Intermediate forms of Charcot-Marie-Tooth neuropathy: a review. Neuromolecular Med. 2006;8(1-2):123-130. doi:10.1385/nmm:8:1-2:123
  46. Lawson VH, Gordon Smith A, Bromberg MB. Assessment of axonal loss in Charcot-Marie- Tooth neuropathies. Exp Neurol. 2003;184(2):753-757. doi:10.1016/S0014-4886(03)00293-0
  47. Rudnik-Schöneborn S, Röhrig D, Nicholson G, Zerres K. Pregnancy and delivery in Charcot- Marie-Tooth disease type 1. Neurology. 1993;43(10):2011-2016. doi:10.1212/wnl.43.10.2011
  48. Fan E, Cheek F, Chlan L, et al. An official American Thoracic Society Clinical Practice guideline: the diagnosis of intensive care unit-acquired weakness in adults. Am J Respir Crit Care Med. 2014;190(12):1437-1446. doi:10.1164/rccm.201411-2011ST
  49. Roland EH. Muscular dystrophy. Pediatr Rev. 2000;21(7):233-238. doi:10.1542/pir.21-7-233
  50. Brown RH Jr. Dystrophin-associated proteins and the muscular dystrophies. Annu Rev Med. 1997;48:457-466. doi:10.1146/annurev.med.48.1.457
  51. Emery AE, Dreifuss FE. Unusual type of benign x-linked muscular dystrophy. J Neurol Neurosurg Psychiatry. 1966;29(4):338-342. doi:10.1136/jnnp.29.4.338
  52. Orrell RW, Tawil R, Forrester J, Kissel JT, Mendell JR, Figlewicz DA. Definitive molecular diagnosis of facioscapulohumeral dystrophy. Neurology. 1999;52(9):1822-1826. doi:10.1212/wnl.52.9.1822
  53. Johannsen S, Kranke P, Reiners K, Schuster F. Besonderheiten im prä- und perioperativen Management [Perioperative management of patients with neuromuscular disorders]. Anasthesiol Intensivmed Notfallmed Schmerzther. 2009;44(11-12):748-756. doi:10.1055/s-0029-1242126
  54. Zeviani M, Amati P, Savoia A. Mitochondrial myopathies. Curr Opin Rheumatol. 1994;6(6):559-567. doi:10.1097/00002281-199411000-00003
  55. Clay AS, Behnia M, Brown KK. Mitochondrial disease: a pulmonary and critical-care medicine perspective. Chest. 2001;120(2):634-648. doi:10.1378/chest.120.2.634
  56. Badr AE, Mychaskiw G 2nd, Eichhorn JH. Metabolic acidosis associated with a new formulation of propofol. Anesthesiology. 2001;94(3):536-538. doi:10.1097/00000542- 200103000-00030
  57. Krivickas LS, Ansved T, Suh D, Frontera WR. Contractile properties of single muscle fibers in myotonic dystrophy. Muscle Nerve. 2000;23(4):529-537. doi:10.1002/(sici)1097- 4598(200004)23:4<529::aid-mus11>3.0.co;2-y
  58. Harper PS: Myotonic Dystrophy, 3rd ed. London, WB Saunders, 2001.
  59. George AL Jr, Crackower MA, Abdalla JA, Hudson AJ, Ebers GC. Molecular basis of Thomsen's disease (autosomal dominant myotonia congenita). Nat Genet. 1993;3(4):305-310. doi:10.1038/ng0493-305
  60. Mitchell MM, Ali HH, Savarese JJ. Myotonia and neuromuscular blocking agents. Anesthesiology. 1978;49(1):44-48. doi:10.1097/00000542-197807000-00014
  61. Jurkat-Rott K, Lehmann-Horn F. Human muscle voltage-gated ion channels and hereditary disease. Curr Opin Pharmacol. 2001;1(3):280-287. doi:10.1016/s1471-4892(01)00050-9
  62. Ashwood EM, Russell WJ, Burrow DD. Hyperkalaemic periodic paralysis and anaesthesia. Anaesthesia. 1992;47(7):579-584. doi:10.1111/j.1365-2044.1992.tb02327.x
  63. Quane KA, Healy JM, Keating KE, et al. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nat Genet. 1993;5(1):51-55. doi:10.1038/ng0993- 51
  64. Lehmann-Horn F, Jurkat-Rott K, Rüdel R. Periodic paralysis: understanding channelopathies. Curr Neurol Neurosci Rep. 2002;2(1):61-69. doi:10.1007/s11910-002-0055- 9
  65. Jurkat-Rott K, Lerche H, Lehmann-Horn F. Skeletal muscle channelopathies. J Neurol. 2002;249(11):1493-1502. doi:10.1007/s00415-002-0871-5
  66. Kleopa KA, Barchi RL. Genetic disorders of neuromuscular ion channels. Muscle Nerve. 2002;26(3):299-325. doi:10.1002/mus.10164
  67. Whitney KD, McNamara JO. Autoimmunity and neurological disease: antibody modulation of synaptic transmission. Annu Rev Neurosci. 1999;22:175-195. doi:10.1146/annurev.neuro.22.1.175
  68. Klingler W, Lehmann-Horn F, Jurkat-Rott K. Complications of anaesthesia in neuromuscular disorders. Neuromuscul Disord. 2005;15(3):195-206. doi:10.1016/j.nmd.2004.10.017
  69. Racca F, Mongini T, Wolfler A, et al. Recommendations for anesthesia and perioperative management of patients with neuromuscular disorders. Minerva Anestesiol. 2013;79(4):419- 433.
  70. Racca F, Del Sorbo L, Mongini T, Vianello A, Ranieri VM. Respiratory management of acute respiratory failure in neuromuscular diseases. Minerva Anestesiol. 2010;76(1):51-62.
  71. Rubino FA. Perioperative management of patients with neurologic disease. Neurol Clin. 2004;22(2):v-276. doi:10.1016/j.ncl.2003.12.005
  72. Supinski GS, Morris PE, Dhar S, Callahan LA. Diaphragm Dysfunction in Critical Illness. Chest. 2018;153(4):1040-1051. doi:10.1016/j.chest.2017.08.1157
  73. Goligher EC, Fan E, Herridge MS, et al. Evolution of Diaphragm Thickness during Mechanical Ventilation. Impact of Inspiratory Effort. Am J Respir Crit Care Med. 2015;192(9):1080-1088. doi:10.1164/rccm.201503-0620OC
  74. Tawakul AA, Al-Doboke AW, Altayyar SA, Alsulami SA, Alfahmi AM, Nooh RT. Guillain- Barré Syndrome in the COVID-19 Pandemic. Neurol Int. 2021;14(1):34-48. Published 2021 Dec 24. doi:10.3390/neurolint14010003
  75. Schmitt HJ, Muenster T. Anesthesia in patients with neuromuscular disorders. Minerva Anestesiol. 2009;75(11):632-637.
  76. Richa FC. Anaesthetic management of a patient with limb-girdle muscular dystrophy for laparoscopic cholecystectomy. Eur J Anaesthesiol. 2011;28(1):72-73. doi:10.1097/EJA.0b013e328340517b
  77. Graham RJ, Athiraman U, Laubach AE, Sethna NF. Anesthesia and perioperative medical management of children with spinal muscular atrophy. Paediatr Anaesth. 2009;19(11):1054- 1063. doi:10.1111/j.1460-9592.2009.03055.x
  78. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9(1):77-93. doi:10.1016/S1474-4422(09)70271-6
  79. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care [published correction appears in Lancet Neurol. 2010 Mar;9(3):237]. Lancet Neurol. 2010;9(2):177-189. doi:10.1016/S1474- 4422(09)70272-8
  80. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management [published correction appears in Lancet Neurol. 2018 Apr 4;:]. Lancet Neurol. 2018;17(3):251-267. doi:10.1016/S1474-4422(18)30024-3
  81. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018;17(4):347-361. doi:10.1016/S1474-4422(18)30025-5
  82. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol. 2018;17(5):445-455. doi:10.1016/S1474- 4422(18)30026-7
  83. Eichhorn JH, Cooper JB, Cullen DJ, Maier WR, Philip JH, Seeman RG. Standards for patient monitoring during anesthesia at Harvard Medical School. JAMA. 1986;256(8):1017-1020.
  84. Ali HH, Savarese JJ. Monitoring of neuromuscular function. Anesthesiology. 1976;45(2):216- 249. doi:10.1097/00000542-197608000-00009
  85. Viby-Mogensen J, Jensen E, Werner M, Nielsen HK. Measurement of acceleration: a new method of monitoring neuromuscular function. Acta Anaesthesiol Scand. 1988;32(1):45-48. doi:10.1111/j.1399-6576.1988.tb02686.x
  86. Бутров А.В., Дробышев М.Ф., Киселевич В.Е. Технология использования миорелаксантов на основе мониторинга нейромышечной проводимости. М.: Изд-во НЦССХ им. А. Н. Бакулева РАМН, 1999: 48.
  87. Vianello A, Arcaro G, Braccioni F, et al. Prevention of extubation failure in high-risk patients with neuromuscular disease. J Crit Care. 2011;26(5):517-524. doi:10.1016/j.jcrc.2010.12.008
  88. Chatwin M, Toussaint M, Gonçalves MR, et al. Airway clearance techniques in neuromuscular disorders: A state of the art review. Respir Med. 2018;136:98-110. doi:10.1016/j.rmed.2018.01.012
  89. Birnkrant DJ. The American College of Chest Physicians consensus statement on the respiratory and related management of patients with Duchenne muscular dystrophy undergoing anesthesia or sedation. Pediatrics. 2009;123 Suppl 4:S242-S244. doi:10.1542/peds.2008-2952J
  90. Luo F, Annane D, Orlikowski D, et al. Invasive versus non-invasive ventilation for acute respiratory failure in neuromuscular disease and chest wall disorders. Cochrane Database Syst Rev. 2017;12(12):CD008380. Published 2017 Dec 4. doi:10.1002/14651858.CD008380.pub2
  91. Servera E, Sancho J, Bañuls P, Marín J. Bulbar impairment score predicts noninvasive volume-cycled ventilation failure during an acute lower respiratory tract infection in ALS. J Neurol Sci. 2015;358(1-2):87-91. doi:10.1016/j.jns.2015.08.027
  92. Davidson AC, Banham S, Elliott M, et al. BTS/ICS guideline for the ventilatory management of acute hypercapnic respiratory failure in adults [published correction appears in Thorax. 2017 Jun;72 (6):588]. Thorax. 2016;71 Suppl 2:ii1-ii35. doi:10.1136/thoraxjnl-2015-208209
  93. Sahni AS, Wolfe L. Respiratory Care in Neuromuscular Diseases. Respir Care. 2018;63(5):601-608. doi:10.4187/respcare.06210
  94. Cabrera Serrano M, Rabinstein AA. Causes and outcomes of acute neuromuscular respiratory failure. Arch Neurol. 2010;67(9):1089-1094. doi:10.1001/archneurol.2010.207
  95. Carr AS, Hoeritzauer AI, Kee R, et al. Acute neuromuscular respiratory failure: a population-based study of aetiology and outcome in Northern Ireland. Postgrad Med J. 2014;90(1062):201-204. doi:10.1136/postgradmedj-2013-132105
  96. Muenster T, Mueller C, Forst J, Huber H, Schmitt HJ. Anaesthetic management in patients with Duchenne muscular dystrophy undergoing orthopaedic surgery: a review of 232 cases. Eur J Anaesthesiol. 2012;29(10):489-494. doi:10.1097/EJA.0b013e3283566789
  97. Ames WA, Hayes JA, Crawford MW. The role of corticosteroids in Duchenne muscular dystrophy: a review for the anesthetist. Paediatr Anaesth. 2005;15(1):3-8. doi:10.1111/j.1460- 9592.2005.01424.x
  98. Sofocleous CT, Schur I, Cooper SG, Quintas JC, Brody L, Shelin R. Sonographically guided placement of peripherally inserted central venous catheters: review of 355 procedures. AJR Am J Roentgenol. 1998;170(6):1613-1616. doi:10.2214/ajr.170.6.9609183
  99. Troianos CA, Hartman GS, Glas KE, et al. Special articles: guidelines for performing ultrasound guided vascular cannulation: recommendations of the American Society of Echocardiography and the Society Of Cardiovascular Anesthesiologists. Anesth Analg. 2012;114(1):46-72. doi:10.1213/ANE.0b013e3182407cd8
  100. Morimoto Y, Mii M, Hirata T, Matayoshi H, Sakabe T. Target-controlled infusion of propofol for a patient with myotonic dystrophy. J Anesth. 2005;19(4):336-338. doi:10.1007/s00540- 005-0348-7
  101. Allen GC. Bispectral index and mitochondrial myopathies. Anesthesiology. 2003;98(1):282-283. doi:10.1097/00000542-200301000-00051
  102. Hara K, Sakura S, Saito Y, Maeda M, Kosaka Y. Epidural anesthesia and pulmonary function in a patient with amyotrophic lateral sclerosis. Anesth Analg. 1996;83(4):878-879. doi:10.1097/00000539-199610000-00040
  103. Gross JB, Bachenberg KL, Benumof JL, et al. Practice guidelines for the perioperative management of patients with obstructive sleep apnea: a report by the American Society of Anesthesiologists Task Force on Perioperative Management of patients with obstructive sleep apnea. Anesthesiology. 2006;104(5):1081-1118. doi:10.1097/00000542-200605000-00026
  104. Upton AR, McComas AJ. The double crush in nerve entrapment syndromes. Lancet. 1973;2(7825):359-362. doi:10.1016/s0140-6736(73)93196-6
  105. Kim SJ, Kim EJ, Min BW, Ban JS, Lee SG, Lee JH. Epidural anesthesia for the patient with type IV spinal muscular atrophy - A case report-. Korean J Anesthesiol. 2010;59 Suppl(Suppl):S65-S68. doi:10.4097/kjae.2010.59.S.S65
  106. Brock M, Guinn C, Jones M. Anesthetic management of an obstetric patient with Charcot-Marie-Tooth disease: a case study. AANA J. 2009;77(5):335-337.
  107. Veyckemans F. Can inhalation agents be used in the presence of a child with myopathy?. Curr Opin Anaesthesiol. 2010;23(3):348-355. doi:10.1097/ACO.0b013e3283393977
  108. de Boer HD, van Esmond J, Booij LH, Driessen JJ. Reversal of rocuronium-induced profound neuromuscular block by sugammadex in Duchenne muscular dystrophy. Paediatr Anaesth. 2009;19(12):1226-1228. doi:10.1111/j.1460-9592.2009.03178.x
  109. Unterbuchner C, Fink H, Blobner M. The use of sugammadex in a patient with myasthenia gravis. Anaesthesia. 2010;65(3):302-305. doi:10.1111/j.1365-2044.2009.06236.x
  110. Driessen JJ. Neuromuscular and mitochondrial disorders: what is relevant to the anaesthesiologist?. Curr Opin Anaesthesiol. 2008;21(3):350-355. doi:10.1097/ACO.0b013e3282f82bcc
  111. Ciafaloni E, Fox DJ, Pandya S, et al. Delayed diagnosis in duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). J Pediatr. 2009;155(3):380-385. doi:10.1016/j.jpeds.2009.02.007
  112. Kyriakides T, Angelini C, Schaefer J, et al. EFNS guidelines on the diagnostic approach to paucior asymptomatic hyperCKemia. Eur J Neurol. 2010;17(6):767-773. doi:10.1111/j.1468-1331.2010.03012.x
  113. Kochi T, Oka T, Mizuguchi T. Epidural anesthesia for patients with amyotrophic lateral sclerosis. Anesth Analg. 1989;68(3):410-412.
  114. Otsuka N, Igarashi M, Shimodate Y, Nakabayashi K, Asano M, Namiki A. Masui. 2004;53(11):1279-1281.
  115. Arai Y, Yoshida T, Mizuno Y, Miyashita T, Goto T. Epidural Anesthesia with Non-invasive Positive Pressure Ventilation for Laparotomy in a Patient with Amyotrophic Lateral Sclerosis. Masui. 2015;64(10):1062-1064.
  116. Naguib M, Flood P, McArdle JJ, Brenner HR. Advances in neurobiology of the neuromuscular junction: implications for the anesthesiologist. Anesthesiology. 2002;96(1):202-231. doi:10.1097/00000542-200201000-00035
  117. Lee D, Lee KC, Kim JY, Park YS, Chang YJ. Total intravenous anesthesia without muscle relaxant in a patient with amyotrophic lateral sclerosis. J Anesth. 2008;22(4):443-445. doi:10.1007/s00540-008-0655-x
  118. Beach TP, Stone WA, Hamelberg W. Circulatory collapse following succinylcholine: report of a patient with diffuse lower motor neuron disease. Anesth Analg. 1971;50(3):431-437.
  119. Rosenbaum KJ, Neigh JL, Strobel GE. Sensitivity to nondepolarizing muscle relaxants in amyotrophic lateral sclerosis: report of two cases. Anesthesiology. 1971;35(6):638-641. doi:10.1097/00000542-197112000-00017
  120. Arnulf I, Similowski T, Salachas F, et al. Sleep disorders and diaphragmatic function in patients with amyotrophic lateral sclerosis. Am J Respir Crit Care Med. 2000;161(3 Pt 1):849-856. doi:10.1164/ajrccm.161.3.9805008
  121. Sato K, Morimoto N, Deguchi K, Ikeda Y, Matsuura T, Abe K. Seven amyotrophic lateral sclerosis patients diagnosed only after development of respiratory failure. J Clin Neurosci. 2014;21(8):1341-1343. doi:10.1016/j.jocn.2013.11.021
  122. Radunovic A, Annane D, Rafiq MK, Mustfa N. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2013;(3):CD004427. Published 2013 Mar 28. doi:10.1002/14651858.CD004427.pub3
  123. Kotani N, Hirota K, Anzawa N, Takamura K, Sakai T, Matsuki A. Motor and sensory disability has a strong relationship to induction dose of thiopental in patients with the hypertropic variety of Charcot-Marie-Tooth syndrome. Anesth Analg. 1996;82(1):182-186. doi:10.1097/00000539-199601000-00034
  124. Naguib M, Samarkandi AH. Response to atracurium and mivacurium in a patient with Charcot-Marie-Tooth disease. Can J Anaesth. 1998;45(1):56-59. doi:10.1007/BF03011994
  125. Cuesta A, Pedrola L, Sevilla T, et al. The gene encoding ganglioside-induced differentiation- associated protein 1 is mutated in axonal Charcot-Marie-Tooth type 4A disease. Nat Genet. 2002;30(1):22-25. doi:10.1038/ng798
  126. Aldwinckle RJ, Carr AS. The anesthetic management of a patient with Emery-Dreifuss muscular dystrophy for orthopedic surgery. Can J Anaesth. 2002;49(5):467-470. doi:10.1007/BF03017922
  127. Bennun M, Goldstein B, Finkelstein Y, Jedeikin R. Continuous propofol anaesthesia for patients with myotonic dystrophy. Br J Anaesth. 2000;85(3):407-409. doi:10.1093/bja/85.3.407
  128. Shiraishi M, Minami K, Kadaya T. A safe anesthetic method using caudal block and ketamine for the child with congenital myotonic dystrophy. Anesth Analg. 2002;94(1):233. doi:10.1097/00000539-200201000-00046
  129. Shapiro F, Sethna N, Colan S, Wohl ME, Specht L. Spinal fusion in Duchenne muscular dystrophy: a multidisciplinary approach. Muscle Nerve. 1992;15(5):604-614. doi:10.1002/mus.880150512
  130. Genever EE. Suxamethonium-induced cardiac arrest in unsuspected pseudohypertrophic muscular dystrophy. Case report. Br J Anaesth. 1971;43(10):984-986. doi:10.1093/bja/43.10.984
  131. Buzello W, Huttarsch H. Muscle relaxation in patients with Duchenne's muscular dystrophy. Use of vecuronium in two patients. Br J Anaesth. 1988;60(2):228-231. doi:10.1093/bja/60.2.228
  132. Uslu M, Mellinghoff H, Diefenbach C. Mivacurium for muscle relaxation in a child with Duchenne's muscular dystrophy. Anesth Analg. 1999;89(2):340-341. doi:10.1097/00000539- 199908000-00017
  133. Nightingale P, Healy TE, McGuinness K. Dystrophia myotonica and atracurium. A case report. Br J Anaesth. 1985;57(11):1131-1135. doi:10.1093/bja/57.11.1131
  134. Kaufman L. Dystrophia myotonica and succinylcholine. Anaesthesia. 2000;55(9):929. doi:10.1046/j.1365-2044.2000.01664-26.x
  135. Buzello W, Krieg N, Schlickewei A. Hazards of neostigmine in patients with neuromuscular disorders. Report of two cases. Br J Anaesth. 1982;54(5):529-534. doi:10.1093/bja/54.5.529
  136. Noordeen MH, Haddad FS, Muntoni F, Gobbi P, Hollyer JS, Bentley G. Blood loss in Duchenne muscular dystrophy: vascular smooth muscle dysfunction?. J Pediatr Orthop B. 1999;8(3):212-215. doi:10.1097/01202412-199907000-00015
  137. Ricker K. Myotonic dystrophy and proximal myotonic myophathy. J Neurol. 1999;246(5):334-338. doi:10.1007/s004150050359
  138. Maslow A, Lisbon A. Anesthetic considerations in patients with mitochondrial dysfunction. Anesth Analg. 1993;76(4):884-886. doi:10.1213/00000539-199304000-00035
  139. Rosaeg OP, Morrison S, MacLeod JP. Anaesthetic management of labour and delivery in the parturient with mitochondrial myopathy. Can J Anaesth. 1996;43(4):403-407. doi:10.1007/BF03011722
  140. Fricker RM, Raffelsberger T, Rauch-Shorny S, et al. Positive malignant hyperthermia susceptibility in vitro test in a patient with mitochondrial myopathy and myoadenylate deaminase deficiency. Anesthesiology. 2002;97(6):1635-1637. doi:10.1097/00000542- 200212000-00044
  141. Carroll JE, Zwillich C, Weil JV, Brooke MH. Depressed ventilatory response in oculocraniosomatic neuromuscular disease. Neurology. 1976;26(2):140-146. doi:10.1212/wnl.26.2.140
  142. Cros D, Palliyath S, DiMauro S, Ramirez C, Shamsnia M, Wizer B. Respiratory failure revealing mitochondrial myopathy in adults. Chest. 1992;101(3):824-828. doi:10.1378/chest.101.3.824
  143. Farag E, Argalious M, Narouze S, DeBoer GE, Tome J. The anesthetic management of ventricular septal defect (VSD) repair in a child with mitochondrial cytopathy. Can J Anaesth. 2002;49(9):958-962. doi:10.1007/BF03016883
  144. Sasano N, Fujita Y, So M, Sobue K, Sasano H, Katsuya H. Anesthetic management of a patient with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) during laparotomy. J Anesth. 2007;21(1):72-75. doi:10.1007/s00540-006- 0449-y
  145. Shipton EA, Prosser DO. Mitochondrial myopathies and anaesthesia. Eur J Anaesthesiol. 2004;21(3):173-178. doi:10.1017/s0265021504003023
  146. Blichfeldt-Lauridsen L, Hansen BD. Anesthesia and myasthenia gravis. Acta Anaesthesiol Scand. 2012;56(1):17-22. doi:10.1111/j.1399-6576.2011.02558.x
  147. Baraka A. Onset of neuromuscular block in myasthenic patients. Br J Anaesth. 1992;69(2):227-228. doi:10.1093/bja/69.2.227-d
  148. Abel M, Eisenkraft JB. Anesthetic implications of myasthenia gravis. Mt Sinai J Med. 2002;69(1-2):31-37.
  149. Sanders DB. Lambert-Eaton myasthenic syndrome: clinical diagnosis, immune-mediated mechanisms, and update on therapies. Ann Neurol. 1995;37 Suppl 1:S63-S73. doi:10.1002/ana.410370708
  150. Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3,4- diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology. 2000;54(3):603-607. doi:10.1212/wnl.54.3.603
  151. Nilsson E, Paloheimo M, Müller K, Heinonen J. Halothane-induced variability in the neuromuscular transmission of patients with myasthenia gravis. Acta Anaesthesiol Scand. 1989;33(5):395-401. doi:10.1111/j.1399-6576.1989.tb02931.x
  152. Rowbottom SJ. Isoflurane for thymectomy in myasthenia gravis. Anaesth Intensive Care. 1989;17(4):444-447. doi:10.1177/0310057X8901700408
  153. Akpolat N, Tilgen H, Gürsoy F, Saydam S, Gürel A. Thoracic epidural anaesthesia and analgesia with bupivacaine for transsternal thymectomy for myasthenia gravis. Eur J Anaesthesiol. 1997;14(2):220-223. doi:10.1046/j.1365-2346.1997.00113.x
  154. D'Angelo R, Gerancher JC. Combined spinal and epidural analgesia in a parturient with severe myasthenia gravis. Reg Anesth Pain Med. 1998;23(2):201-203. doi:10.1097/00115550-199823020-00015
  155. Eisenkraft JB, Book WJ, Mann SM, Papatestas AE, Hubbard M. Resistance to succinylcholine in myasthenia gravis: a dose-response study. Anesthesiology. 1988;69(5):760-763. doi:10.1097/00000542-198811000-00021
  156. Baraka A. Suxamethonium block in the myasthenic patient. Correlation with plasma cholinesterase. Anaesthesia. 1992;47(3):217-219. doi:10.1111/j.1365-2044.1992.tb02122.x
  157. Smith CE, Donati F, Bevan DR. Cumulative dose-response curves for atracurium in patients with myasthenia gravis. Can J Anaesth. 1989;36(4):402-406. doi:10.1007/BF03005338
  158. De Haes A, Proost JH, De Baets MH, Stassen MH, Houwertjes MC, Wierda JM. Pharmacokinetic-pharmacodynamic modeling of rocuronium in case of a decreased number of acetylcholine receptors: a study in myasthenic pigs. Anesthesiology. 2003;98(1):133-142. doi:10.1097/00000542-200301000-00022
  159. Brown JC, Charlton JE. A study of sensitivity to curare in myasthenic disorders using a regional technique. J Neurol Neurosurg Psychiatry. 1975;38(1):27-33. doi:10.1136/jnnp.38.1.27
  160. Small S, Ali HH, Lennon VA, Brown RH Jr, Carr DB, de Armendi A. Anesthesia for an unsuspected Lambert-Eaton myasthenic syndrome with autoantibodies and occult small cell lung carcinoma. Anesthesiology. 1992;76(1):142-145. doi:10.1097/00000542-199201000- 00022
  161. Wright RB: Myasthenia. In Klawans HL, Goetz CG, Tattler CM (eds): Textbook of Clinical Neuropharmacology and Therapeutics. New York, Raven Press, 1992, pp 505-516.
  162. Яхно Н.Н., Штульман Д.P. Болезни нервной системы. В 2 т. (4-е издание).- Медицина, 2005 г.
  163. Tugasworo D, Kurnianto A, Retnaningsih, Andhitara Y, Ardhini R, Budiman J. The relationship between myasthenia gravis and COVID-19: a systematic review. Egypt J Neurol Psychiatr Neurosurg. 2022;58(1):83. doi:10.1186/s41983-022-00516-3
  164. Heliopoulos I, Patlakas G, Vadikolias K, et al. Maximal voluntary ventilation in myasthenia gravis. Muscle Nerve. 2003;27(6):715-719. doi:10.1002/mus.10378
  165. Galassi G, Marchioni A. Myasthenia gravis at the crossroad of COVID-19: focus on immunological and respiratory interplay. Acta Neurol Belg. 2021;121(3):633-642. doi:10.1007/s13760-021-01612-6
  166. Roper J, Fleming ME, Long B, Koyfman A. Myasthenia Gravis and Crisis: Evaluation and Management in the Emergency Department. J Emerg Med. 2017;53(6):843-853. doi:10.1016/j.jemermed.2017.06.009
  167. Dhont S, Derom E, Van Braeckel E, Depuydt P, Lambrecht BN. The pathophysiology of 'happy' hypoxemia in COVID-19. Respir Res. 2020;21(1):198. Published 2020 Jul 28. doi:10.1186/s12931-020-01462-5
  168. Tobin MJ, Laghi F, Jubran A. Why COVID-19 Silent Hypoxemia Is Baffling to Physicians. Am J Respir Crit Care Med. 2020;202(3):356-360. doi:10.1164/rccm.202006- 2157CP
  169. Neumann B, Angstwurm K, Mergenthaler P, et al. Myasthenic crisis demanding mechanical ventilation: A multicenter analysis of 250 cases [published correction appears in Neurology. 2020 Apr 21;94(16):724. Schneider, Haucke [corrected to Schneider, Hauke]]. Neurology. 2020;94(3):e299-e313. doi:10.1212/WNL.0000000000008688
  170. International MG/COVID-19 Working Group, Jacob S, Muppidi S, et al. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci. 2020;412:116803. doi:10.1016/j.jns.2020.116803
  171. Hoang P, Hurtubise B, Muppidi S. Clinical Reasoning: Therapeutic considerations in myasthenic crisis due to COVID-19 infection. Neurology. 2020;95(18):840-843. doi:10.1212/WNL.0000000000010651
  172. Heiman-Patterson T, Martino C, Rosenberg H, Fletcher J, Tahmoush A. Malignant hyperthermia in myotonia congenita. Neurology. 1988;38(5):810-812. doi:10.1212/wnl.38.5.810
  173. Arcas M, Sánchez-Ortega JL, García-Muñoz M, Alonso B, del Yelmo F, López-Rodríguez F. Anestesia para cesárea en un caso de miotonía congénita [Anesthesia for cesarean delivery in a case of myotonia congenita]. Rev Esp Anestesiol Reanim. 1996;43(4):147-149.
  174. Bisinotto FM, Fabri DC, Calçado MS, Perfeito PB, Tostes LV, Sousa GD. Anesthesia for videolaparoscopic cholecystectomy in a patient with Steinert disease. Case report and review of the literature. Rev Bras Anestesiol. 2010;60(2):181-110. doi:10.1016/s0034-7094(10)70024-6
  175. Haeseler G, Störmer M, Bufler J, et al. Propofol blocks human skeletal muscle sodium channels in a voltage-dependent manner. Anesth Analg. 2001;92(5):1192-1198. doi:10.1097/00000539-200105000-00021
  176. Haeseler G, Störmer M, Mohammadi B, et al. The anesthetic propofol modulates gating in paramyotonia congenita mutant muscle sodium channels. Muscle Nerve. 2001;24(6):736-743. doi:10.1002/mus.1064
  177. Weller JF, Elliott RA, Pronovost PJ. Spinal anesthesia for a patient with familial hyperkalemic periodic paralysis. Anesthesiology. 2002;97(1):259-260. doi:10.1097/00000542-200207000-00033
  178. Allison KR. Muscular dystrophy versus mitochondrial myopathy: the dilemma of the undiagnosed hypotonic child. Paediatr Anaesth. 2007;17(1):1-6. doi:10.1111/j.1460-9592.2006.02106.x
  179. Flewellen EH, Bodensteiner JB: Anesthetic experience in a patient with hyperkalemic periodic paralysis. Anesth Rev 7:44, 1980.
  180. Viscomi CM, Ptacek LJ, Dudley D. Anesthetic management of familial hypokalemic periodic paralysis during parturition. Anesth Analg. 1999;88(5):1081-1082. doi:10.1097/00000539-199905000-00021
  181. Siler JN, Discavage WJ. Anesthetic management of hypokalemic periodic paralysis. Anesthesiology. 1975;43(4):489-490. doi:10.1097/00000542-197510000-00018
  182. Löfgren A, Hahn RG. Hypokalemia from intercostal nerve block. Reg Anesth. 1994;19(4):247-254.
  183. Zisfein J, Sivak M, Aron AM, Bender AN. Isaacs' syndrome with muscle hypertrophy reversed by phenytoin therapy. Arch Neurol. 1983;40(4):241-242. doi:10.1001/archneur.1983.04050040071012
  184. van den Berg JS, van Engelen BG, Boerman RH, de Baets MH. Acquired neuromyotonia: superiority of plasma exchange over high-dose intravenous human immunoglobulin. J Neurol. 1999;246(7):623-625. doi:10.1007/s004150050419
  185. Ashizawa T, Butler IJ, Harati Y, Roongta SM. A dominantly inherited syndrome with continuous motor neuron discharges. Ann Neurol. 1983;13(3):285-290. doi:10.1002/ana.410130310
  186. Hosokawa S, Shinoda H, Sakai T, Kato M, Kuroiwa Y. Electrophysiological study on limb myokymia in three women. J Neurol Neurosurg Psychiatry. 1987;50(7):877-881. doi:10.1136/jnnp.50.7.877
  187. Morgan PJ. Peripartum management of a patient with Isaacs' syndrome. Can J Anaesth. 1997;44(11):1174-1177. doi:10.1007/BF03013340
  188. McNicol ED, Tzortzopoulou A, Cepeda MS, Francia MB, Farhat T, Schumann R. Single-dose intravenous paracetamol or propacetamol for prevention or treatment of postoperative pain: a systematic review and meta-analysis. Br J Anaesth. 2011;106(6):764-775. doi:10.1093/bja/aer107
  189. Birnkrant DJ, Panitch HB, Benditt JO, et al. American College of Chest Physicians consensus statement on the respiratory and related management of patients with Duchenne muscular dystrophy undergoing anesthesia or sedation. Chest. 2007;132(6):1977-1986. doi:10.1378/chest.07-0458
  190. Maund E, McDaid C, Rice S, Wright K, Jenkins B, Woolacott N. Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs for the reduction in morphine-related side-effects after major surgery: a systematic review. Br J Anaesth. 2011;106(3):292-297. doi:10.1093/bja/aeq406
  191. Fowler SJ, Symons J, Sabato S, Myles PS. Epidural analgesia compared with peripheral nerve blockade after major knee surgery: a systematic review and meta-analysis of randomized trials. Br J Anaesth. 2008;100(2):154-164. doi:10.1093/bja/aem373
  192. Walker KJ, McGrattan K, Aas-Eng K, Smith AF. Ultrasound guidance for peripheral nerve blockade. Cochrane Database Syst Rev. 2009;(4):CD006459. Published 2009 Oct 7. doi:10.1002/14651858.CD006459.pub2
  193. Niranjan V, Bach JR. Noninvasive management of pediatric neuromuscular ventilatory failure. Crit Care Med. 1998;26(12):2061-2065. doi:10.1097/00003246-199812000-00042
  194. Ruscic KJ, Grabitz SD, Rudolph MI, Eikermann M. Prevention of respiratory complications of the surgical patient: actionable plan for continued process improvement. Curr Opin Anaesthesiol. 2017;30(3):399-408. doi:10.1097/ACO.0000000000000465
  195. Wang CH, Finkel RS, Bertini ES, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007;22(8):1027-1049. doi:10.1177/0883073807305788
  196. Almenrader N, Patel D. Spinal fusion surgery in children with non-idiopathic scoliosis: is there a need for routine postoperative ventilation?. Br J Anaesth. 2006;97(6):851-857. doi:10.1093/bja/ael273
  197. Marchant WA, Fox R. Postoperative use of a cough-assist device in avoiding prolonged intubation. Br J Anaesth. 2002;89(4):644-647. doi:10.1093/bja/aef227
  198. Лебединский. К.М., Триадский. А.А., Оболенский. С.В. Злокачественная гипертермия: фармакогенетически обусловленный острый массивный рабдомиолиз. Анестезиол. и реаниматол. 2008; 4: 66–70.
  199. Wang CH, Bonnemann CG, Rutkowski A, et al. Consensus statement on standard of care for congenital muscular dystrophies. J Child Neurol. 2010;25(12):1559-1581. doi:10.1177/0883073810381924
  200. Bach JR, Gonçalves MR, Hamdani I, Winck JC. Extubation of patients with neuromuscular weakness: a new management paradigm. Chest. 2010;137(5):1033-1039. doi:10.1378/chest.09-2144
  201. Miranda Rocha AR, Martinez BP, Maldaner da Silva VZ, Forgiarini Junior LA. Early mobilization: Why, what for and how?. Med Intensiva. 2017;41(7):429-436. doi:10.1016/j.medin.2016.10.003
  202. Белкин А.А., Алашеев А.М., Белкин В.А., и др. Реабилитация в отделении реанимации и интенсивной терапии (РеабИТ). Методические рекомендации Союза реабилитологов России и Федерации анестезиологов и реаниматологов. Вестник интенсивной терапии им. А.И. Салтанова. 2022; 2: 7–40. doi:10.21320/1818-474X-2022-2-7-40
  203. Shousha AA, Sanfilippo M, Sabba A, Pinchera P. Sugammadex and reversal of neuromuscular block in adult patient with duchenne muscular dystrophy. Case Rep Anesthesiol. 2014;2014:680568. doi:10.1155/2014/680568
  204. Shimauchi T, Yamaura K, Sugibe S, Hoka S. Usefulness of sugammadex in a patient with Becker muscular dystrophy and dilated cardiomyopathy. Acta Anaesthesiol Taiwan. 2014;52(3):146-148. doi:10.1016/j.aat.2014.02.005
  205. De Boer HD, Van Egmond J, Driessen JJ, Booij LHJD. Sugammadex in patients with myasthenia gravis. Anaesthesia. 2010;65(6):653. doi:10.1111/j.1365-2044.2010.06360.x
  206. Jakubiak J, Gaszyński T, Gaszyński W. Neuromuscular block reversal with sugammadex in a morbidly obese patient with myasthenia gravis. Anaesthesiol Intensive Ther. 2012;44(1):28-30.
  207. Sungur Ulke Z, Yavru A, Camci E, Ozkan B, Toker A, Senturk M. Rocuronium and sugammadex in patients with myasthenia gravis undergoing thymectomy. Acta Anaesthesiol Scand. 2013;57(6):745-748. doi:10.1111/aas.12123
  208. Vymazal T, Krecmerova M, Bicek V, Lischke R. Feasibility of full and rapid neuromuscular blockade recovery with sugammadex in myasthenia gravis patients undergoing surgery - a series of 117 cases. Ther Clin Risk Manag. 2015;11:1593-1596. Published 2015 Oct 15. doi:10.2147/TCRM.S93009
  209. Sungur Z, Sentürk M. Anaesthesia for thymectomy in adult and juvenile myasthenic patients. Curr Opin Anaesthesiol. 2016;29(1):14-19. doi:10.1097/ACO.0000000000000272
  210. Ortiz-Gómez JR, Palacio-Abizanda FJ, Fornet-Ruiz I. Failure of sugammadex to reverse rocuronium-induced neuromuscular blockade: a case report. Eur J Anaesthesiol. 2014;31(12):708-709. doi:10.1097/EJA.0000000000000082

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*